Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 07, 2020 11:30 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Dosing of First Healthy Volunteer in Phase I Clinical Study of SARS-CoV-2 Neutralizing Antibody JS016 in China

First healthy volunteer has been dosed in a Phase I study of JS016, the first SARS-CoV-2 neutralizing antibody to enter the clinical stage in ChinaJunshi and Lilly will co-develop JS016 globallyJS016...
June 01, 2020 10:50 ET | Source: Junshi Biosciences

Junshi Biosciences and Merck Announce Collaboration to Explore Promising New COMBINATION Treatment for Head and Neck Cancer Patients in China

SHANGHAI, China, June 01, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEK: 1877), a China-based biopharmaceutical company specializing in discovery, development and commercialization of novel...
May 26, 2020 10:10 ET | Source: Junshi Biosciences

Nature Publishes Preclinical Characterization and Primate Efficacy Data on Junshi Biosciences’ COVID-19 Neutralizing Antibodies

CB6 demonstrated prophylactic and treatment effects in rhesus monkeys Clinical testing expected to begin in second quarter in collaboration with Eli Lilly and Company SHANGHAI, China, May 26, 2020...
May 07, 2020 18:10 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Locally Advanced or Metastatic Urothelial Carcinoma

SHANGHAI, China, May 07, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization...
May 04, 2020 09:13 ET | Source: Junshi Biosciences

Junshi Biosciences and Lilly to Co-develop Antibody Therapies for the Prevention and Treatment of COVID-19

SHANGHAI and INDIANAPOLIS, May 04, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) and Eli Lilly and Company (NYSE: LLY) announced today they have entered into an agreement to co-develop...
April 30, 2020 10:56 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Acceptance of a Supplemental NDA in China for Toripalimab in Advanced Nasopharyngeal Carcinoma

SHANGHAI, China, April 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
March 30, 2020 21:29 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Approval of Proposed A-Share Listing by the Listing Committee for the Shanghai Stock Exchange (SSE) STAR Market

SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and...
March 30, 2020 12:43 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Full-Year 2019 Financial Results and Business Updates

SHANGHAI, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development and commercialization of...
March 30, 2020 12:30 ET | Source: Junshi Biosciences

Junshi Biosciences Receives Orphan Drug Designation from the U.S. FDA for Toripalimab in Combination with Pfizer’s Axitinib for the Treatment of Mucosal Melanoma

SHANGHAI, China, March 30, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) today announced that the U.S. Food and Drug Administration (FDA) has recently granted Orphan Drug Designation...
March 20, 2020 12:15 ET | Source: Junshi Biosciences

Junshi Biosciences Announces Co-Development Agreement with IMCAS to Advance Neutralizing Antibodies as Potential Novel Treatment for COVID-19

SHANGHAI, China, March 20, 2020 (GLOBE NEWSWIRE) -- Junshi Biosciences (HKEX: 1877) announced that it has recently signed a collaboration agreement with the Institute of Microbiology of the Chinese...